Small Caps

Acurx Pharmaceuticals Earns $12 Price Target From Maxim Group; Ibezapolstat Stays In Focus To Treat C. difficile (NASDAQ: ACXP)

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Send this to a friend